Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™Business Wire • 09/03/21
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® TechnologiesBusiness Wire • 08/23/21
Glaukos Corporation's (GKOS) CEO Tom Burns on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/29/21
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual MeetingBusiness Wire • 07/22/21
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5Business Wire • 07/15/21
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee ScheduleBusiness Wire • 07/14/21
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TRBusiness Wire • 06/10/21
Glaukos Announces Australia's TGA Regulatory Approval for PRESERFLO™ MicroShuntBusiness Wire • 06/08/21